Do you find our website user friendly?
Yes   No

Belviq Withdrawn from the US Market Due to Potential Cancer Risk

On February 13, 2020 The U.S. Food and Drug Administration (FDA) requested that the manufacturer of Belviq, Belviq XR (lorcaserin) voluntarily withdraw the weight-loss drug from the U.S. market because a safety clinical trial shows an increased occurrence of cancer with long term use. The drug manufacturer, Eisai has submitted a request to voluntarily withdraw the drug.

Although the risk was small (0.6% increased risk compared to those taking placebo), the FDA felt this warranted removal from the market. There does not appear to be an increased risk of cancer in the initial months of treatment, but the risk is increased with longer duration on Belviq.

You should stop taking Belviq and call the office to schedule an appointment to discuss alternative weight-loss medicines and/or weight management programs.

The FDA is not recommending special screening for patients who have taken Belviq.  As with any individual patient, regardless of prior Belviq treatment, standard screening recommendations for cancer should be implemented.

Author
Scott Isaacs, MD Endocrinologist and Weight Loss Specialist

You Might Also Enjoy...

Stop Relying on Willpower to Lose Weight

We all face difficult diet scenarios every day. All it takes is a trip to the office break room to put your entire day’s success in jeopardy! The best way to successfully manage your calories is to have strategies that you can tap into when you are in a to

Change is Hard – So Let’s Make it Easier!

Have you ever thought, “I know what I need to do, I just have to do it!”? Moving from the “knowing” to the “doing” is such a common barrier for all of us because, let’s face it, change is hard.

Now Offering COVID-19 Antibody Testing

We are pleased to announce that Atlanta Endocrine Associates is now offering COVID-19 antibody testing. We are offering this service to all current patients and their families.

Fatty Liver Disease: The Hidden Epidemic

Nonalcoholic fatty liver disease, or NAFLD (pronounced na-ful-dee) is one of the most widespread and yet frequently underdiagnosed diseases in the United States and worldwide. Fatty liver disease is the number one cause of chronic liver disease in the U.S.